We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
Read MoreHide Full Article
Pfizer, Inc. (PFE - Free Report) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
The pharma giant has a mixed record of earnings surprises. The company’s earnings surpassed expectations in two of the last four quarters while missing in the other two, with an average positive surprise of 4.36%.
Pfizer’s shares rose 4% in the past one year compared with an increase of 5.4% for the Zacks classified Large-Cap Pharma industry.
Factors to Consider
New products like Xalkori (lung cancer), Xeljanz (rheumatoid arthritis) and Ibrance (breast cancer) as well as older products like Lyrica (neuropathic pain) should contribute to the top line meaningfully. Also, revenues from the blockbuster prostate cancer drug Xtandi, added to Pfizer’s portfolio following the Sep 2016 Medivation acquisition, should propel U.S. revenues.
Meanwhile, the Hospira acquisition should continue to be an important growth driver as well. Also, Pfizer launched Inflectra, a biosimilar version of Johnson & Johnson (JNJ - Free Report) and Merck’s blockbuster drug Remicade in Nov 2016, which should generate more sales in the first quarter of 2017. Also, Eucrisa (crisaborole) topical ointment, added to Pfizer’s portfolio with the Jun 2016 Anacor acquisition, was approved by the FDA in Dec 2016 for the treatment of eczema. The product should also contribute to the top line in the first quarter.
However, Pfizer will continue to face headwinds in the form of loss of exclusivity on key products like Zyvox and Celebrex and the expiration of a few co-promotion agreements, which will continue to hamper top-line growth. Blockbuster drug Enbrel’s sales will continue to be hurt in the quarter due to biosimilar competition. The Prevnar/Prevenar 13 vaccines franchise should also continue to see lower sales.
Meanwhile, the bottom line should be driven by cost savings and share buybacks. However, new product launch expenses and R&D investments are expected to hurt profits.
On the first-quarter call, investor focus is expected to remain on the company’s performance along with that of new products and pipeline progress including biosimilars and immuno-oncology.
In March, Pfizer announced marketing approvals for its RA drug Xeljanz in the EU and China; said that its breast cancer drug Ibrance’s accelerated approval was converted to regular approval and announced accelerated FDA approval for avelumab for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer. Though these positive regulatory updates will not have any impact on first-quarter sales, these should add to the top line in later quarters.
Earnings Whispers
Our proven model does not conclusively show that Pfizer is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is 0.00% as both the Most Accurate estimate as well as the Zacks Consensus Estimate stand at 67 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Pfizer’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
Pfizer, Inc. (PFE - Free Report) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
The pharma giant has a mixed record of earnings surprises. The company’s earnings surpassed expectations in two of the last four quarters while missing in the other two, with an average positive surprise of 4.36%.
Pfizer’s shares rose 4% in the past one year compared with an increase of 5.4% for the Zacks classified Large-Cap Pharma industry.
Factors to Consider
New products like Xalkori (lung cancer), Xeljanz (rheumatoid arthritis) and Ibrance (breast cancer) as well as older products like Lyrica (neuropathic pain) should contribute to the top line meaningfully. Also, revenues from the blockbuster prostate cancer drug Xtandi, added to Pfizer’s portfolio following the Sep 2016 Medivation acquisition, should propel U.S. revenues.
Meanwhile, the Hospira acquisition should continue to be an important growth driver as well. Also, Pfizer launched Inflectra, a biosimilar version of Johnson & Johnson (JNJ - Free Report) and Merck’s blockbuster drug Remicade in Nov 2016, which should generate more sales in the first quarter of 2017. Also, Eucrisa (crisaborole) topical ointment, added to Pfizer’s portfolio with the Jun 2016 Anacor acquisition, was approved by the FDA in Dec 2016 for the treatment of eczema. The product should also contribute to the top line in the first quarter.
However, Pfizer will continue to face headwinds in the form of loss of exclusivity on key products like Zyvox and Celebrex and the expiration of a few co-promotion agreements, which will continue to hamper top-line growth. Blockbuster drug Enbrel’s sales will continue to be hurt in the quarter due to biosimilar competition. The Prevnar/Prevenar 13 vaccines franchise should also continue to see lower sales.
Meanwhile, the bottom line should be driven by cost savings and share buybacks. However, new product launch expenses and R&D investments are expected to hurt profits.
On the first-quarter call, investor focus is expected to remain on the company’s performance along with that of new products and pipeline progress including biosimilars and immuno-oncology.
In March, Pfizer announced marketing approvals for its RA drug Xeljanz in the EU and China; said that its breast cancer drug Ibrance’s accelerated approval was converted to regular approval and announced accelerated FDA approval for avelumab for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer. Though these positive regulatory updates will not have any impact on first-quarter sales, these should add to the top line in later quarters.
Earnings Whispers
Our proven model does not conclusively show that Pfizer is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Zacks ESP: The Earnings ESP is 0.00% as both the Most Accurate estimate as well as the Zacks Consensus Estimate stand at 67 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Pfizer’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings beat.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Pfizer, Inc. Price and EPS Surprise
Pfizer, Inc. Price and EPS Surprise | Pfizer, Inc. Quote
Stocks to Consider
Stocks in the pharma sector that have both a positive ESP and a favorable Zacks Rank are:
Amgen, Inc. (AMGN - Free Report) has an Earnings ESP of +2.33% and a Zacks Rank #3. The company is scheduled to release results on Apr 26.
Scheduled to release results on May 2, Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +2.77% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information >>